Quick Answer
Cellectar Biosciences, Inc. reported Cash and Equivalents of $13.20 million for fiscal year 2025.
Cellectar Biosciences, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $13.20M | -43.3% |
| 2024 | $23.29M | +143.5% |
| 2023 | $9.56M | -51.9% |
| 2022 | $19.87M | -44.4% |
| 2021 | $35.70M | -37.5% |
| 2020 | $57.17M | +438.5% |
| 2019 | $10.61M | -19.9% |
| 2018 | $13.26M | +32.5% |
| 2017 | $10.01M | -12.6% |
| 2016 | $11.44M | +192.5% |
| 2015 | $3.91M | -58.5% |
| 2014 | $9.42M | +289.6% |
| 2013 | $2.42M | -48.3% |
| 2012 | $4.68M | -15.0% |
| 2011 | $5.51M | +717.2% |
| 2010 | $673.7K | -31.3% |
| 2009 | $980.1K | — |
| 2002 | $0.00 | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $12.55M | -63.4% | +13.7% |
| June 30, 2025 | $11.04M | -57.3% | -20.6% |
| March 31, 2025 | $13.91M | -65.3% | -40.3% |
| December 31, 2024 | $23.29M | +143.5% | -32.0% |
| September 30, 2024 | $34.26M | +80.5% | +32.5% |
| June 30, 2024 | $25.87M | +402.0% | -35.4% |
| March 31, 2024 | $40.03M | +215.6% | +318.5% |
| December 31, 2023 | $9.56M | -51.9% | -49.6% |
- Cellectar Biosciences, Inc. showed a decrease of -43.3% in Cash and Equivalents compared to the prior fiscal year.
- The most recent figure is from Cellectar Biosciences, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 4, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: